Although they demonstrated the capacity of sGC activators to dilate cerebral blood vessels, which resulted in small infarct volumes following stroke, they did not specifically investigate the impact of these compounds either on collateral flow or in the presence of stroke comorbidities. This evidence concerns the gene SGCB and Stroke.